Procyclidine hydrochloride
| File:Procyclidine hydrochloride.png | |
| Clinical data | |
|---|---|
| Routes of administration | oral, im, iv |
| ATC code | |
| Pharmacokinetic data | |
| Protein binding | ~100%-albumin |
| Elimination half-life | ~12 h |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C19H30ClNO |
| Molar mass | 323.9 g/mol |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Procyclidine hydrochloride is an anticholinergic drug principally used for the treatment of:
- Drug-induced parkinsonism, akathisia and acute dystonia;
- Parkinson disease; and
- Idiopathic or secondary dystonia.
Uses
It is used in patients with schizophrenia to reduce the side effects of antipsychotic treatment, such as parkinsonism and akathisia.
Procyclidine is also a second-line drug for the treatment of Parkinson's disease. It improves tremor but not rigidity or bradykinesia.
Procyclidine is also sometimes used for the treatment of dystonia (but not tardive dyskinesia), a rare disorder that causes abnormal muscle contraction, resulting in twisting postures of limbs, trunk, or face.
Signs of Overdose
Signs of procyclidine overdose are those of an anticholinergic and include confusion, agitation and sleeplessness that can last up to or more than 24 hours. Pupils become dilated and unreactive to light. Tachycardia (fast heart beat), as well as auditory and visual hallucinations have also been reported.
Other known symptoms of overdose are: clumsiness or unsteadiness, being severely drowsy, having a severely dry mouth, nose, or throat, having an altered mood or other mental changes, seizures, being short of breath or having troubled breathing, a dry and warm, flushed skin.
A suspected overdose with severe life-threatening symptoms should immediately be brought to medical attention, where reversal can be attempted with physostigmine administered intravenously or subcutaneously.
References
- British National Formulary (45 ed.). 2003. Unknown parameter
|month=ignored (help)
- Pages with script errors
- Pages with broken file links
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Pages with citations using unsupported parameters
- Drugs
- Anticholinergics
- Dopamine reuptake inhibitors
- Muscarinic antagonists
- Tardive dyskinesia